Richard Cook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3072569/publications.pdf

Version: 2024-02-01

356 papers

20,648 citations

68 h-index 134 g-index

364 all docs

364 docs citations

times ranked

364

18286 citing authors

#	Article	IF	Citations
1	Assessing the accuracy of predictive models with interval-censored data. Biostatistics, 2022, 23, 18-33.	1.5	8
2	Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study. Arthritis Care and Research, 2022, 74, 1244-1253.	3.4	9
3	Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic. Arthritis Care and Research, 2022, 74, 1254-1262.	3.4	4
4	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2022, 74, 1430-1434.	3.4	22
5	Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. Nature Medicine, 2022, , .	30.7	1
6	A hierarchical metaâ€analysis for settings involving multiple outcomes across multiple cohorts. Stat, 2022, 11, .	0.4	1
7	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. Journal of Rheumatology, 2022, 49, 523-530.	2.0	18
8	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2022, 53, 151950.	3.4	0
9	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	5.6	5
10	Classical Regression and Predictive Modeling. World Neurosurgery, 2022, 161, 251-264.	1.3	4
11	Marker-dependent observation and carry-forward of internal covariates in Cox regression. Lifetime Data Analysis, 2022, 28, 560-584.	0.9	2
12	Multistate models for the natural history of cancer progression. British Journal of Cancer, 2022, 127, 1279-1288.	6.4	3
13	Life history analysis with multistate models: A review and some current issues. Canadian Journal of Statistics, 2022, 50, 1270-1298.	0.9	2
14	Independence conditions and the analysis of life history studies with intermittent observation. Biostatistics, 2021, 22, 455-481.	1.5	11
15	The illness-death model for family studies. Biostatistics, 2021, 22, 482-503.	1.5	1
16	The Pattern of Musculoskeletal Complaints in Patients With Suspected Psoriatic Arthritis and Their Correlation With Physical Examination and Ultrasound. Journal of Rheumatology, 2021, 48, 214-221.	2.0	9
17	The impact of an alcohol policy change on developmental trajectories of youth alcohol use: examination of a natural experiment in Canada. Canadian Journal of Public Health, 2021, 112, 210-218.	2.3	5
18	Gene-Based Association Testing of Dichotomous Traits With Generalized Functional Linear Mixed Models Using Extended Pedigrees: Applications to Age-Related Macular Degeneration. Journal of the American Statistical Association, 2021, 116, 531-545.	3.1	3

#	Article	IF	CITATIONS
19	Selection models for efficient twoâ€phase design of family studies. Statistics in Medicine, 2021, 40, 254-270.	1.6	2
20	Analysis of timeâ€toâ€event for observational studies: Guidance to the use of intensity models. Statistics in Medicine, 2021, 40, 185-211.	1.6	29
21	Known and Unknown Unknowns in Making Erythrocyte Transfusion Decisions. Anesthesiology, 2021, 134, 359-362.	2.5	0
22	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. Seminars in Arthritis and Rheumatism, 2021, 51, 144-149.	3.4	10
23	Geneâ€based analysis of biâ€variate survival traits via functional regressions with applications to eye diseases. Genetic Epidemiology, 2021, 45, 455-470.	1.3	1
24	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Seminars in Arthritis and Rheumatism, 2021, 51, 464-468.	3.4	17
25	Semiparametric recurrent event vs timeâ€toâ€firstâ€event analyses in randomized trials: Estimands and model misspecification. Statistics in Medicine, 2021, 40, 3823-3842.	1.6	2
26	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	1.6	21
27	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2021, 80, 1429-1435.	0.9	11
28	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 547-552.	3.4	11
29	Propensity Score Analysis for a Semi-Continuous Exposure Variable: A Study of Gestational Alcohol Exposure and Childhood Cognition. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 1390-1413.	1.1	7
30	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. Journal of Rheumatology, 2021, 48, 1824-1829.	2.0	5
31	Effects of prenatal alcohol exposure on cognitive and behavioral development: Findings from a hierarchical metaâ€analysis of data from six prospective longitudinal U.S. cohorts. Alcoholism: Clinical and Experimental Research, 2021, 45, 2040-2058.	2.4	21
32	Understanding COVIDâ€19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Populationâ€based analysis of SARSâ€CoVâ€2 Testing. Arthritis Care and Research, 2021, , .	3.4	8
33	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	30.7	206
34	Transforming primary care for older Canadians living with frailty: mixed methods study protocol for a complex primary care intervention. BMJ Open, $2021, 11, e042911$.	1.9	1
35	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, 2021, , .	5.2	7
36	Identifying patterns of alcohol use among secondary school students in Canada: A multilevel latent class analysis. Addictive Behaviors, 2020, 100, 106120.	3.0	12

#	Article	IF	CITATIONS
37	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. Rheumatology, 2020, 59, 1340-1346.	1.9	88
38	Composite likelihood for aggregate data from clustered multistate processes under intermittent observation. Communications in Statistics - Theory and Methods, 2020, 49, 2913-2930.	1.0	0
39	Testing the heritability and parentâ€ofâ€origin hypotheses for ages at onset of psoriatic arthritis under biased sampling. Biometrics, 2020, 76, 293-303.	1.4	3
40	Response to: â€~Can biomarkers differentiate psoriatic arthritis from osteoarthritis?' by Tian <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e113-e113.	0.9	1
41	Multistate analysis from crossâ€sectional and auxiliary samples. Statistics in Medicine, 2020, 39, 387-408.	1.6	1
42	Limitations of the particle immunofiltration assay test for diagnosis of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, E250-E254.	4.1	1
43	Regression with incomplete multivariate surrogate responses for a latent covariate. Biostatistics and Epidemiology, 2020, 4, 247-264.	0.4	0
44	Determining the long-term health burden and risk of sequelae for 14 foodborne infections in British Columbia, Canada: protocol for a retrospective population-based cohort study. BMJ Open, 2020, 10, e036560.	1.9	4
45	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e640-e648.	4.6	16
46	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. Seminars in Arthritis and Rheumatism, 2020, 50, 571-575.	3.4	23
47	Failure time studies with intermittent observation and losses to followâ€up. Scandinavian Journal of Statistics, 2020, 47, 1035-1063.	1.4	2
48	A Mixture Model for Bivariate Interval-Censored Failure Times with Dependent Susceptibility. Statistics in Biosciences, 2020, 12, 37-62.	1.2	3
49	Mitigating bias from intermittent measurement of timeâ€dependent covariates in failure time analysis. Statistics in Medicine, 2020, 39, 1833-1845.	1.6	2
50	The association between synovial fluid serine proteinase activity and response to intra-articular corticosteroid injection in psoriatic arthritis. Clinical Rheumatology, 2020, 39, 2355-2361.	2.2	1
51	Remission in psoriatic arthritis: Definition and predictors. Seminars in Arthritis and Rheumatism, 2020, 50, 1494-1499.	3.4	7
52	Declining levels of serum chemokine (Câ€X motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*. British Journal of Dermatology, 2020, 183, 920-927.	1.5	14
53	Liver Abnormalities in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 847-853.	2.0	18
54	Linear mixed models for association analysis of quantitative traits with nextâ€generation sequencing data. Genetic Epidemiology, 2019, 43, 189-206.	1.3	5

#	Article	IF	Citations
55	The effect of omitted covariates in marginal and partially conditional recurrent event analyses. Lifetime Data Analysis, 2019, 25, 280-300.	0.9	6
56	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48, 638-643.	3.4	18
57	On estimands arising from misspecified semiparametric rateâ€based analysis of recurrent episodic conditions. Statistics in Medicine, 2019, 38, 4977-4998.	1.6	1
58	Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models. Computer Methods and Programs in Biomedicine, 2019, 177, 269-275.	4.7	6
59	Dependence modeling for multiâ€type recurrent events via copulas. Statistics in Medicine, 2019, 38, 4066-4082.	1.6	9
60	A new perspective on loss to followâ€up in failure time and life history studies. Statistics in Medicine, 2019, 38, 4583-4610.	1.6	7
61	Geneâ€based association analysis of survival traits via functional regressionâ€based mixed effect cox models for related samples. Genetic Epidemiology, 2019, 43, 952-965.	1.3	4
62	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The) Tj ETQq0 (0 0 rgBT /C)verlock 10 Tf
63	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. Arthritis and Rheumatology, 2019, 71, 1651-1659.	5.6	22
64	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 796-801.	0.9	34
65	Score tests based on a finite mixture model of Markov processes under intermittent observation. Statistics in Medicine, 2019, 38, 3013-3025.	1.6	1
66	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	1.6	11
67	Cohort study design for illness-death processes with disease status under intermittent observation. Biostatistics and Epidemiology, 2019, 3, 178-200.	0.4	O
68	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Populationâ€Based Study. Arthritis Care and Research, 2019, 71, 1084-1091.	3.4	68
69	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion, 2019, 59, 482-491.	1.6	51
70	Copula-based score test for bivariate time-to-event data, with application to a genetic study of AMD progression. Lifetime Data Analysis, 2019, 25, 546-568.	0.9	14
71	Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis — GRAPPA Ultrasound Working Group. Journal of Rheumatology, 2019, 46, 384-390.	2.0	50
72	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. Clinical Rheumatology, 2019, 38, 1063-1066.	2.2	3

#	Article	IF	Citations
73	Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019). Statistical Methods in Medical Research, 2019, 28, 1597-1598.	1.5	О
74	Comment to the reply letter: Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019). Statistical Methods in Medical Research, 2019, 28, 1603-1603.	1.5	0
75	Identifying trajectories of alcohol use in a sample of secondary school students in Ontario and Alberta: longitudinal evidence from the COMPASS study. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2019, 39, 244-253.	1.1	7
76	Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial. Blood, 2019, 134, 896-896.	1.4	0
77	The Association Between <scp>HLA</scp> Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 756-762.	5.6	14
78	Genome-wide analysis of disease progression in age-related macular degeneration. Human Molecular Genetics, 2018, 27, 929-940.	2.9	67
79	Design of cancer trials based on progressionâ€free survival with intermittent assessment. Statistics in Medicine, 2018, 37, 1947-1959.	1.6	5
80	Variable selection and prediction in biased samples with censored outcomes. Lifetime Data Analysis, 2018, 24, 72-93.	0.9	4
81	Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. Arthritis and Rheumatology, 2018, 70, 408-416.	5.6	49
82	Second-Order Estimating Equations for Clustered Current Status Data from Family Studies Using Response-Dependent Sampling. Statistics in Biosciences, 2018, 10, 160-183.	1,2	3
83	Observing Blood Management Programs through the Retrospectroscope. Anesthesiology, 2018, 129, 1060-1062.	2.5	1
84	Cost-effective Design of Growth Studies with Aggregation and Tracking. Journal of Biometrics & Biostatistics, 2018, 09, .	4.0	1
85	Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion, 2018, 58, 2841-2860.	1.6	12
86	Tracing studies in cohorts with attrition: Selection models for efficient sampling. Statistics in Medicine, 2018, 37, 2354-2366.	1.6	3
87	Statistical methods for incomplete data: Some results on model misspecification. Statistical Methods in Medical Research, 2017, 26, 248-267.	1.5	6
88	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. Journal of Rheumatology, 2017, 44, 286-291.	2.0	39
89	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1700-1705.	3.4	14
90	A two-phase model for chronic disease processes under intermittent inspection. Statistics in Medicine, 2017, 36, 2016-2031.	1.6	0

#	Article	IF	Citations
91	Demonstrating therapeutic equivalence of a new and established pharmaceutical or intervention: a guide for the nonâ€statistician. Transfusion, 2017, 57, 1343-1346.	1.6	1
92	Bivariate Analysis of Age-Related Macular Degeneration Progression Using Genetic Risk Scores. Genetics, 2017, 206, 119-133.	2.9	46
93	Group O <scp>RBC</scp> s: where is universal donor blood being used. Vox Sanguinis, 2017, 112, 336-342.	1.5	20
94	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	4.6	34
95	Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus. Journal of Clinical Rheumatology, 2017, 23, 301-307.	0.9	4
96	Goodnessâ€ofâ€fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals. Statistics in Medicine, 2017, 36, 362-377.	1.6	3
97	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. Arthritis and Rheumatology, 2017, 69, 622-629.	5.6	93
98	Understanding nonâ€inferiority trials and tests for the nonâ€statistician: when to use them and how to interpret them. Transfusion, 2017, 57, 240-243.	1.6	3
99	Analysis of Chronic Disease Processes Based on Cohort and Registry Data. , 2017, , 305-325.		1
100	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Research and Therapy, 2017, 19, 189.	3. 5	57
101	Transfusionâ€related alloimmunization in children: epidemiology and effects of chemotherapy. Vox Sanguinis, 2016, 111, 299-307.	1.5	9
102	Gene-Based Association Analysis for Censored Traits Via Fixed Effect Functional Regressions. Genetic Epidemiology, 2016, 40, 133-143.	1.3	12
103	Exposure to <scp>ABO</scp> â€nonidentical blood associated with increased inâ€hospital mortality in patients with group <scp>A</scp> blood. Transfusion, 2016, 56, 550-557.	1.6	18
104	Augmented composite likelihood for copula modeling in family studies under biased sampling. Biostatistics, 2016, 17, 437-452.	1.5	9
105	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. Journal of Rheumatology, 2016, 43, 1844-1851.	2.0	11
106	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	27.0	278
107	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. Journal of Rheumatology, 2016, 43, 1057-1062.	2.0	7
108	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 915-923.	5 . 6	197

#	Article	lF	Citations
109	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. Journal of Rheumatology, 2016, 43, 362-366.	2.0	30
110	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews, 2016, 30, 25-29.	2.0	15
111	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. Lancet Haematology,the, 2016, 3, e246-e254.	4.6	57
112	Sieve estimation in a Markov illness-death process under dual censoring. Biostatistics, 2016, 17, 350-363.	1.5	12
113	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1680-1686.	0.9	85
114	A conditional frailty model for bivariate interval-truncated failure time data: an application to a study on siblings diagnosed with schizophrenia. Journal of Medical Statistics and Informatics, 2016, 4, 1.	1.0	5
115	Adaptive sampling in twoâ€phase designs: a biomarker study for progression in arthritis. Statistics in Medicine, 2015, 34, 2899-2912.	1.6	22
116	Analysis of intervalâ€censored recurrent event processes subject to resolution. Biometrical Journal, 2015, 57, 725-742.	1.0	4
117	Exploratory studies on the age of transfused blood and inâ€hospital mortality in patients with cardiovascular diagnoses. Transfusion, 2015, 55, 364-372.	1.6	25
118	Penalized regression for intervalâ€censored times of disease progression: Selection of HLA markers in psoriatic arthritis. Biometrics, 2015, 71, 782-791.	1.4	26
119	Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients. Arthritis Care and Research, 2015, 67, 264-272.	3.4	63
120	Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood, 2015, 126, 486-493.	1.4	39
121	Bias in progressionâ€free survival analysis due to intermittent assessment of progression. Statistics in Medicine, 2015, 34, 3181-3193.	1.6	21
122	A Coxâ€Aalen Model for Interval ensored Data. Scandinavian Journal of Statistics, 2015, 42, 414-426.	1.4	13
123	Sample size and robust marginal methods for clusterâ€randomized trials with censored event times. Statistics in Medicine, 2015, 34, 901-923.	1.6	6
124	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 813-817.	0.9	138
125	Multiple imputation for the analysis of incomplete compound variables. Canadian Journal of Statistics, 2015, 43, 240-264.	0.9	2
126	Does Cox analysis of a randomized survival study yield a causal treatment effect?. Lifetime Data Analysis, 2015, 21, 579-593.	0.9	136

#	Article	IF	CITATIONS
127	Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis. Arthritis Care and Research, 2015, 67, 842-847.	3.4	45
128	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1830-1835.	0.9	70
129	Event History Analysis., 2015,, 295-304.		O
130	Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. Journal of Gastrointestinal Oncology, 2015, 6, 274-9.	1.4	6
131	Changing Pattern of Sputum Cell Counts During Successive Exacerbations of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 628-35.	1.6	4
132	Marginal Methods for Multivariate Failure Times Under Event-Dependent Censoring. International Journal of Statistics and Probability, 2014, 3, .	0.3	0
133	Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 1417-1422.	3.4	25
134	Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2014, 311, 2191.	7.4	167
135	A dynamic Mover–Stayer model for recurrent event processes subject to resolution. Lifetime Data Analysis, 2014, 20, 404-423.	0.9	7
136	Statistical Issues in Modeling Chronic Disease in Cohort Studies. Statistics in Biosciences, 2014, 6, 127-161.	1.2	25
137	Composite likelihood for joint analysis of multiple multistate processes via copulas. Biostatistics, 2014, 15, 690-705.	1.5	9
138	Responseâ€dependent twoâ€phase sampling designs for biomarker studies. Canadian Journal of Statistics, 2014, 42, 268-284.	0.9	16
139	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis, 2014, 112, 692-699.	3.4	67
140	Statistical Models and Methods for Incomplete Data in Randomized Clinical Trials., 2014, , 1-27.		2
141	Measurement Error for Age of Onset in Prevalent Cohort Studies. Applied Mathematics, 2014, 05, 1672-1683.	0.4	3
142	Statistical Considerations in the Use of Composite Endpoints in Time to Event Analyses. , 2014, , 209-226.		0
143	The Design of Intervention Trials Involving Recurrent and Terminal Events. Statistics in Biosciences, 2013, 5, 261-285.	1.2	4
144	Rehabilitation in Home Care Is Associated With Functional Improvement and Preferred Discharge. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1038-1047.	0.9	49

#	Article	IF	CITATIONS
145	A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. European Journal of Haematology, 2013, 90, 121-126.	2.2	28
146	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic featuresâ€"An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	2.4	34
147	A copula model for marked point processes. Lifetime Data Analysis, 2013, 19, 463-489.	0.9	6
148	Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis. Journal of Rheumatology, 2013, 40, 866-871.	2.0	48
149	Regression with incomplete covariates and leftâ€truncated timeâ€toâ€event data. Statistics in Medicine, 2013, 32, 1004-1015.	1.6	2
150	Clinical trials evaluating pathogenâ€reduced platelet products: methodologic issues and recommendations. Transfusion, 2013, 53, 1843-1855.	1.6	14
151	Inverse probability weighted estimating equations for randomized trials in transfusion medicine. Statistics in Medicine, 2013, 32, 4380-4399.	1.6	1
152	Authors' redress on â€~Robustness of methods for blinded sample size reâ€estimation with overdispersed count data'. Statistics in Medicine, 2013, 32, 3955-3957.	1.6	2
153	The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood, 2013, 122, 1946-1953.	1.4	168
154	Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. Dermatology, 2013, 226, 19-27.	2.1	6
155	Response-Dependent Sampling with Clustered and Longitudinal Data. Lecture Notes in Statistics, 2013, , 157-181.	0.2	5
156	Number Needed to Treat for Recurrent Events. Journal of Biometrics & Biostatistics, 2013, 04, .	4.0	4
157	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood, 2013, 122, 3651-3651.	1.4	6
158	The association between smoking and the development of psoriatic arthritis among psoriasis patients. Annals of the Rheumatic Diseases, 2012, 71, 219-224.	0.9	75
159	Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration. Oncologist, 2012, 17, 645-652.	3.7	23
160	Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial. BMJ Open, 2012, 2, e001080.	1.9	12
161	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	1.4	111
162	Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. Clinical Cancer Research, 2012, 18, 6348-6355.	7.0	76

#	Article	IF	Citations
163	Testing for Monotone Trend in Recurrent Event Processes. Technometrics, 2012, 54, 147-158.	1.9	7
164	Misspecification of Cox regression models with composite endpoints. Statistics in Medicine, 2012, 31, 3545-3562.	1.6	16
165	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. Journal of Thrombosis and Haemostasis, 2012, 10, 148-150.	3.8	15
166	The effect of blood storage duration on inâ€hospital mortality: a randomized controlled pilot feasibility trial. Transfusion, 2012, 52, 1203-1212.	1.6	61
167	Marginal methods for clustered longitudinal binary data with incomplete covariates. Journal of Statistical Planning and Inference, 2012, 142, 2819-2831.	0.6	2
168	The Impact of Retardance Pattern Variability on Nerve Fiber Layer Measurements over Time Using GDx with Variable and Enhanced Corneal Compensation., 2011, 52, 4516.		11
169	The Association Between Diurnal Variation of Optic Nerve Head Topography and Intraocular Pressure and Ocular Perfusion Pressure in Untreated Primary Open-angle Glaucoma. Journal of Glaucoma, 2011, 20, 44-50.	1.6	9
170	Composite outcomes in clinical trials: what are they and when should they be used?. Transfusion, 2011, 51, 11-13.	1.6	17
171	Causal inference in nonrandomized studies via propensity score methods. Transfusion, 2011, 51, 2536-2539.	1.6	6
172	Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group. Trials, 2011, 12, 48.	1.6	4
173	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
174	Information in the sample covariate distribution in prevalent cohorts. Statistics in Medicine, 2011, 30, 1397-1409.	1.6	8
175	Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care and Research, 2011, 63, 619-622.	3.4	81
176	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care and Research, 2011, 63, 1091-1097.	3.4	112
177	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care and Research, 2011, 63, 1440-1447.	3.4	30
178	Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care and Research, 2011, 63, 1729-1735.	3.4	214
179	A robust pairwise likelihood method for incomplete longitudinal binary data arising in clusters. Canadian Journal of Statistics, 2011, 39, 34-51.	0.9	33
180	Zoledronic acid use in cancer patients. Cancer, 2011, 117, 11-23.	4.1	46

#	Article	IF	CITATIONS
181	Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castrationâ€resistant nonmetastatic prostate cancer. Cancer, 2011, 117, 2077-2085.	4.1	152
182	Whole stimulated salivary flow: Correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sj \tilde{A} ¶gren's syndrome but not patients with sicca. Arthritis and Rheumatism, 2011, 63, 2014-2020.	6.7	58
183	Progressive multi-state models for informatively incomplete longitudinal data. Journal of Statistical Planning and Inference, 2011, 141, 80-93.	0.6	7
184	Clinical Correlates of Urolithiasis in Ankylosing Spondylitis. Journal of Rheumatology, 2011, 38, 1953-1956.	2.0	9
185	Iron-containing micronutrient powder provided to children with moderate-to-severe malnutrition increases hemoglobin concentrations but not the risk of infectious morbidity: a randomized, double-blind, placebo-controlled, noninferiority safety trial. American Journal of Clinical Nutrition, 2011. 94. 585-593.	4.7	26
186	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Annals of the Rheumatic Diseases, 2011, 70, 2152-2154.	0.9	183
187	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Präention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. Laboratoriums Medizin. 2011. 35. 45-54.	0.6	0
188	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	2.0	16
189	Effect of Pregnancy on Ankylosing Spondylitis: A Case-Control Study. Journal of Rheumatology, 2011, 38, 2442-2444.	2.0	39
190	Recurrent event analyses. Lifetime Data Analysis, 2010, 16, 449-450.	0.9	1
190	Recurrent event analyses. Lifetime Data Analysis, 2010, 16, 449-450. Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153.	0.9	4
	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences,		
191	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast	1.2	4
191 192	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779. Estimating functions for evaluating treatment effects in clusterâ€randomized longitudinal studies in	1.2 2.5	62
191 192 193	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779. Estimating functions for evaluating treatment effects in clusterâ€randomized longitudinal studies in the presence of dropâ€out and nonâ€compliance. Canadian Journal of Statistics, 2010, 38, 232-255. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational	1.2 2.5 0.9	62
191 192 193	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779. Estimating functions for evaluating treatment effects in clusterâ€randomized longitudinal studies in the presence of dropâ€out and nonâ€compliance. Canadian Journal of Statistics, 2010, 38, 232-255. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care and Research, 2010, 62, 970-976. Analysis of intervalâ€censored disease progression data via multiâ€state models under a nonignorable	1.2 2.5 0.9	4 62 2 110
191 192 193 194	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779. Estimating functions for evaluating treatment effects in clusterâ€randomized longitudinal studies in the presence of dropâ€out and nonâ€compliance. Canadian Journal of Statistics, 2010, 38, 232-255. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care and Research, 2010, 62, 970-976. Analysis of intervalâ€censored disease progression data via multiâ€state models under a nonignorable inspection process. Statistics in Medicine, 2010, 29, 1175-1189. A copulaâ€based mixed Poisson model for bivariate recurrent events under eventâ€dependent censoring.	1.2 2.5 0.9 3.4	4 62 2 110 27

#	Article	IF	CITATIONS
199	Antiâ€PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of nonâ€drug risk factors and evidence for a stoichiometryâ€based model of immunization. Journal of Thrombosis and Haemostasis, 2010, 8, 504-512.	3.8	51
200	Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. Biometrics, 2010, 66, 415-425.	1.4	2
201	Inverse Probability of Censoring Weighted Estimates of Kendall's Ï,, for Gap Time Analyses. Biometrics, 2010, 66, 1145-1152.	1.4	12
202	Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 2010, 24, 1043-1049.	7.2	91
203	Time and predictors of response to tumour necrosis factor-Â blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology, 2010, 49, 1361-1366.	1.9	29
204	Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology, 2010, 49, 1367-1373.	1.9	70
205	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Annals of the Rheumatic Diseases, 2010, 69, 2160-2164.	0.9	66
206	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology, 2010, 49, 1399-1405.	1.9	142
207	Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 809-815.	2.0	94
208	Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal, 2010, 159, 737-743.e1.	2.7	101
209	CANadian Network and Centre for Trials INternationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. Canadian Journal of Cardiology, 2010, 26, 353-358.	1.7	10
210	Weighted Generalized Estimating Functions for Longitudinal Response and Covariate Data That Are Missing at Random. Journal of the American Statistical Association, 2010, 105, 336-353.	3.1	48
211	Oral iron supplementation with a micronutrient powder (Sprinkles®) provided to children with moderateâ€toâ€severe malnutrition does not increase infectious morbidity risk: a randomized, doubleâ€blind, placeboâ€controlled, nonâ€inferiority safety trial. FASEB Journal, 2010, 24, 94.7.	0.5	0
212	Robust Estimation of Mean Functions and Treatment Effects for Recurrent Events Under Event-Dependent Censoring and Termination: Application to Skeletal Complications in Cancer Metastatic to Bone. Journal of the American Statistical Association, 2009, 104, 60-75.	3.1	53
213	FALL-RELATED HIP FRACTURES. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1199-1199.	3.6	2
214	Second-order estimating equations for the analysis of clustered current status data. Biostatistics, 2009, 10, 756-772.	1.5	11
215	Risk Factors for Hip Fracture in Older Home Care Clients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 403-410.	3.6	61
216	Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer, 2009, 9, 272.	2.6	39

#	Article	lF	CITATIONS
217	Likelihood analysis of joint marginal and conditional models for longitudinal categorical data. Canadian Journal of Statistics, 2009, 37, 182-205.	0.9	10
218	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis and Rheumatism, 2009, 61, 1235-1242.	6.7	104
219	The analysis of multivariate recurrent events with partially missing event types. Lifetime Data Analysis, 2009, 15, 41-58.	0.9	16
220	Twoâ€stage design of clinical trials involving recurrent events. Statistics in Medicine, 2009, 28, 2617-2638.	1.6	22
221	Measuring and reporting the effect of an intervention: relative measures. Transfusion, 2009, 49, 9-12.	1.6	0
222	Measuring and reporting the effect of an intervention: absolute measures. Transfusion, 2009, 49, 2022-2023.	1.6	1
223	Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. Journal of Thrombosis and Haemostasis, 2009, 7, 676-684.	3.8	141
224	A Bivariate Mover–Stayer Model for Interval-Censored Recurrent Event Data: Application to Joint Damage in Rheumatology. Communications in Statistics - Theory and Methods, 2009, 38, 3389-3405.	1.0	2
225	Robust Estimation of State Occupancy Probabilities for Interval-Censored Multistate Data: An Application Involving Spondylitis in Psoriatic Arthritis. Communications in Statistics - Theory and Methods, 2009, 38, 3307-3325.	1.0	3
226	A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood, 2009, 113, 1564-1573.	1.4	150
227	Studies of the immune response in heparin-induced thrombocytopenia. Blood, 2009, 113, 4963-4969.	1.4	157
228	Analysis of a nonsusceptible fraction with current status data. Statistics in Medicine, 2008, 27, 2715-2730.	1.6	9
229	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer, 2008, 113, 193-201.	4.1	243
230	A Multistate Model for Bivariate Intervalâ€Censored Failure Time Data. Biometrics, 2008, 64, 1100-1109.	1.4	26
231	The role of noninferiority designs in clinical research. Transfusion, 2008, 48, 1050-1052.	1.6	6
232	Analysis of Interval-Censored Data from Clustered Multistate Processes: Application to Joint Damage in Psoriatic Arthritis. Journal of the Royal Statistical Society Series C: Applied Statistics, 2008, 57, 553-566.	1.0	19
233	P61. Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC). Cancer Treatment Reviews, 2008, 34, 28-29.	7.7	2
234	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	7.7	108

#	Article	IF	Citations
235	Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity. Journal of Thoracic Oncology, 2008, 3, 228-236.	1.1	155
236	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 01-12.	3.4	20
237	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 134-45.	3.4	55
238	Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity. Oncologist, 2007, 12, 1035-1043.	3.7	92
239	Regression analysis of multivariate panel count data. Biostatistics, 2007, 9, 234-248.	1.5	35
240	Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. Annals of Internal Medicine, 2007, 146, 25.	3.9	477
241	Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer. Urology, 2007, 70, 315-319.	1.0	62
242	Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 346-353.	1.4	24
243	Transition Models for Multivariate Longitudinal Binary Data. Journal of the American Statistical Association, 2007, 102, 211-223.	3.1	15
244	Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 2007, 110, 1860-1867.	4.1	559
245	Non-inferiority trial design for recurrent events. Statistics in Medicine, 2007, 26, 4563-4577.	1.6	6
246	A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion, 2007, 48, 071003012013009-???.	1.6	53
247	Designing laboratory-based research studies: is it time for a change?. Transfusion, 2007, 47, 2336-2337.	1.6	1
248	Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder Blood, 2007, 110, 2148-2148.	1.4	2
249	International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. Journal of Rheumatology, 2007, 34, 1733-9.	2.0	57
250	International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	2.0	74
251	Design issues with clinical experimental platelet transfusion studies. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 106-113.	0.2	1
252	Reliability of electrocardiogram interpretation in critically ill patients*. Critical Care Medicine, 2006, 34, 1338-1343.	0.9	44

#	Article	IF	CITATIONS
253	A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, 2006, 46, 903-911.	1.6	45
254	Implications of Model Misspecification in Robust Tests for Recurrent Events. Lifetime Data Analysis, 2006, 12, 69-95.	0.9	12
255	Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin. Anesthesia and Analgesia, 2006, 102, 731-737.	2.2	71
256	Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. European Respiratory Journal, 2006, 27, 483-494.	6.7	548
257	Multistate Analysis of Skeletal Events in Patients with Bone Metastases. Clinical Cancer Research, 2006, 12, 6264s-6269s.	7.0	14
258	Clinical and radiological damage in psoriatic arthritis. Annals of the Rheumatic Diseases, 2006, 65, 478-481.	0.9	73
259	Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2006, 12, 3361-3367.	7.0	156
260	The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica, 2006, 91, 1530-7.	3.5	110
261	Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106, 3791-3796.	1.4	271
262	Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion, 2005, 45, 896-903.	1.6	21
263	Robust Tests for Treatment Effects Based on Censored Recurrent Event Data Observed over Multiple Periods. Biometrics, 2005, 61, 692-701.	1.4	10
264	Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. Journal of Critical Care, 2005, 20, 357-363.	2.2	76
265	Statistical methods for multivariate interval-censored recurrent events. Statistics in Medicine, 2005, 24, 671-691.	1.6	39
266	Anterior Optic Nerve Capillary Blood Flow Response to Diurnal Variation of Mean Ocular Perfusion Pressure in Early Untreated Primary Open-Angle Glaucoma., 2005, 46, 4581.		31
267	Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. Journal of Clinical Oncology, 2005, 23, 4925-4935.	1.6	493
268	Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 2918-2925.	1.6	430
269	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute, 2005, 97, 59-69.	6.3	522
270	Relative Change in Diurnal Mean Ocular Perfusion Pressure: A Risk Factor for the Diagnosis of Primary Open-Angle Glaucoma., 2005, 46, 561.		86

#	Article	IF	Citations
271	Survival-Adjusted Multiple-Event Analysis for the Evaluation of Treatment Effects of Zoledronic Acid in Patients with Bone Metastases from Solid Tumors. Supportive Cancer Therapy, 2005, 2, 234-240.	0.3	26
272	A Revisit of the Criteria To Define Remission in Patients with Idiopathic Thrombocytopenia Undergoing Splenectomy Blood, 2005, 106, 3020-3020.	1.4	33
273	A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant Blood, 2005, 106, 4183-4183.	1.4	0
274	Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics, 2004, 5, 129-143.	1.5	33
275	Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion, 2004, 44, 1135-1142.	1.6	45
276	A Conditional Markov Model for Clustered Progressive Multistate Processes under Incomplete Observation. Biometrics, 2004, 60, 436-443.	1.4	38
277	Marginal Analysis of Incomplete Longitudinal Binary Data: A Cautionary Note on LOCF Imputation. Biometrics, 2004, 60, 820-828.	1.4	71
278	Prediction of falls using a risk assessment tool in the acute care setting. BMC Medicine, 2004, 2, 1.	5.5	115
279	Safe abortion: WHO technical and policy guidance. International Journal of Gynecology and Obstetrics, 2004, 86, 79-84.	2.3	26
280	Clinical Endpoints for Assessing Bisphosphonate Efficacy in the Prevention of Skeletal Complications of Bone Metastases. European Urology Supplements, 2004, 3, 34-39.	0.1	6
281	The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis Blood, 2004, 104, 2718-2718.	1.4	0
282	The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. Journal of Rheumatology, 2004, 31, 1126-31.	2.0	60
283	Regression modeling with recurrent events and time-dependent interval-censored marker data. Lifetime Data Analysis, 2003, 9, 275-291.	0.9	10
284	Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporosis International, 2003, 14, 677-682.	3.1	155
285	Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporosis International, 2003, 14, 913-917.	3.1	81
286	Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 2003, 43, 742-752.	1.6	85
287	Incremental net benefit in randomized clinical trials with quality-adjusted survival. Statistics in Medicine, 2003, 22, 353-362.	1.6	43
288	A 6-Mo Home-Based Exercise Program May Slow Vertebral Height Loss. Journal of Clinical Densitometry, 2003, 6, 391-400.	1.2	10

#	Article	IF	Citations
289	Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis. Biostatistics, 2003, 4, 479-494.	1.5	21
290	Monitoring the evolutionary process of quality: Risk-adjusted charting to track outcomes in intensive care. Critical Care Medicine, 2003, 31, 1676-1682.	0.9	66
291	Marginal Analysis of Point Processes with Competing Risks. Handbook of Statistics, 2003, 23, 349-361.	0.6	3
292	Analysis of repeated events. Statistical Methods in Medical Research, 2002, 11, 141-166.	1.5	117
293	A generalized mover-stayer model for panel data. Biostatistics, 2002, 3, 407-420.	1.5	46
294	Using inverse-weighting in cost-effectiveness analysis with censored data. Statistical Methods in Medical Research, 2002, 11, 539-551.	1.5	49
295	Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, S10-S18.	1.3	90
296	Marginal Methods for Incomplete Longitudinal Data Arising in Clusters. Journal of the American Statistical Association, 2002, 97, 1071-1080.	3.1	63
297	SEMIPARAMETRIC CONFIDENCE INTERVALS BASED ON ESTIMATING FUNCTIONS. Communications in Statistics - Theory and Methods, 2002, 31, 1701-1708.	1.0	2
298	Selection effects in randomized trials with count data. Statistics in Medicine, 2002, 21, 515-531.	1.6	18
299	SECOND ORDER ESTIMATING EQUATIONS FOR CLUSTERED LONGITUDINAL BINARY DATA WITH MISSING OBSERVATIONS. , 2002, , .		2
300	When should an effective treatment be used? Journal of Clinical Epidemiology, 2001, 54, 253-262.	5.0	111
301	Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study. Lancet, The, 2001, 358, 1941-1945.	13.7	120
302	Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone. Journal of the National Cancer Institute, 2001, 93, 534-538.	6.3	54
303	Multiple organ dysfunction: Baseline and serial component scores. Critical Care Medicine, 2001, 29, 2046-2050.	0.9	116
304	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	302
305	Synthesis of Evidence from Epidemiological Studies with Interval-Censored Exposure Due to Grouping. Biometrics, 2001, 57, 671-680.	1.4	9
306	Agreement between Alternative Classifications of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 490-493.	5.6	71

#	Article	IF	CITATIONS
307	Healthâ€related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	2
308	Remission in psoriatic arthritis. Journal of Rheumatology, 2001, 28, 1045-8.	2.0	58
309	Estimation of Operating Characteristics for Dependent Diagnostic Tests Based on Latent Markov Models. Biometrics, 2000, 56, 1109-1117.	1.4	27
310	Interobserver Variation in Interpreting Chest Radiographs for the Diagnosis of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 85-90.	5.6	245
311	A meta-analysis of case-control and cohort studies with interval-censored exposure data: application to chorionic villus sampling. Biostatistics, 2000, 1, 203-217.	1.5	13
312	Methods for assessing responsiveness. Journal of Clinical Epidemiology, 2000, 53, 459-468.	5.0	1,224
313	Monitoring surgical performance using risk-adjusted cumulative sum charts. Biostatistics, 2000, 1, 441-452.	1.5	371
314	Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. Journal of Rheumatology, 2000, 27, 1892-5.	2.0	94
315	Adjusted Score Tests of Homogeneity for Poisson Processes. Journal of the American Statistical Association, 1999, 94, 308-319.	3.1	14
316	The Utility of Mixed-Form Likelihoods. Biometrics, 1999, 55, 284-288.	1.4	4
317	A Mixed Model for Two-State Markov Processes Under Panel Observation. Biometrics, 1999, 55, 915-920.	1.4	25
317	A Mixed Model for Two-State Markov Processes Under Panel Observation. Biometrics, 1999, 55, 915-920. Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524.	0.9	25 17
318	Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524.		17
318	Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524. Monitoring paired binary surgical outcomes using cumulative sum charts., 1999, 18, 69-86.		17 53
318 319 320	Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524. Monitoring paired binary surgical outcomes using cumulative sum charts., 1999, 18, 69-86. Two-state mixed renewal processes for chronic disease., 1999, 18, 175-188. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical	0.9	17 53 19
318 319 320 321	Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524. Monitoring paired binary surgical outcomes using cumulative sum charts., 1999, 18, 69-86. Two-state mixed renewal processes for chronic disease., 1999, 18, 175-188. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Critical Care Medicine, 1999, 27, 2812-2817. Adjusted Score Tests of Homogeneity for Poisson Processes. Journal of the American Statistical	0.9	17 53 19 238

#	Article	IF	CITATIONS
325	A 1-Year Community-Based Health Economic Study of Ciprofloxacin vs Usual Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. Chest, 1998, 113, 131-141.	0.8	147
326	HLA markers and progression in psoriatic arthritis. Journal of Rheumatology, 1998, 25, 730-3.	2.0	72
327	A Logistic-Bivariate Normal Model for Overdispersed Two-State Markov Processes. Biometrics, 1997, 53, 358.	1.4	17
328	Modeling two-state disease processes with random effects., 1997, 3, 315-335.		17
329	DISCUSSION OF PAPER BY WEI AND GLIDDEN. Statistics in Medicine, 1997, 16, 841-851.	1.6	22
330	MARGINAL ANALYSIS OF RECURRENT EVENTS AND A TERMINATING EVENT. , 1997, 16, 911-924.		163
331	Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. Journal of Rheumatology, 1997, 24, 511-7.	2.0	133
332	A logistic model for trend in 2 x 2 x kappa tables with applications to meta-analyses. Biometrics, 1997, 53, 352-7.	1.4	1
333	A logistic-bivariate normal model for overdispersed two-state Markov processes. Biometrics, 1997, 53, 358-64.	1.4	3
334	Interim Monitoring of Longitudinal Comparative Studies with Recurrent Event Responses. Biometrics, 1996, 52, 1311.	1.4	35
335	Design Considerations in Crossover Trials with a Single Interim Analysis and Serial Patient Entry. Biometrics, 1996, 52, 732.	1.4	6
336	Robust Tests for Treatment Comparisons Based on Recurrent Event Responses. Biometrics, 1996, 52, 557.	1.4	71
337	Incorporating Surrogate Endpoints into Group Sequential Trials. Biometrical Journal, 1996, 38, 119-130.	1.0	4
338	Coupled error spending functions for parallel bivariate sequential tests. Biometrics, 1996, 52, 442-50.	1.4	4
339	Robust tests for treatment comparisons based on recurrent event responses. Biometrics, 1996, 52, 557-71.	1.4	4
340	Design considerations in crossover trials with a single interim analysis and serial patient entry. Biometrics, 1996, 52, 732-9.	1.4	0
341	Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics, 1996, 52, 1311-23.	1.4	9
342	Conditional inference for subject-specific and marginal agreement: Two families of agreement measures. Canadian Journal of Statistics, 1995, 23, 333-344.	0.9	39

#	Article	IF	CITATIONS
343	The design and analysis of randomized trials with recurrent events. Statistics in Medicine, 1995, 14, 2081-2098.	1.6	46
344	The number needed to treat: a clinically useful measure of treatment effect. BMJ: British Medical Journal, 1995, 310, 452-454.	2.3	1,615
345	Interim analyses in 2 x 2 crossover trials. Biometrics, 1995, 51, 932-45.	1.4	0
346	Interim monitoring of bivariate responses using repeated confidence intervals. Contemporary Clinical Trials, 1994, 15, 187-200.	1.9	21
347	Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics, 1994, 50, 1146-52.	1.4	13
348	Canadian Hemodialysis Morbidity Study. American Journal of Kidney Diseases, 1992, 19, 214-234.	1.9	515
349	Stress ulcer prophylaxis in the critically III: A meta-analysis. American Journal of Medicine, 1991, 91, 519-527.	1.5	213
350	Incidence of Clinically Important Bleeding in Mechanically Ventilated Patients. Journal of Intensive Care Medicine, 1991, 6, 167-174.	2.8	44
351	International developments in abortion laws: 1977-88 American Journal of Public Health, 1988, 78, 1305-1311.	2.7	23
352	Nested doubly robust estimating equations forÂcausal analysis with an incomplete effect modifier. Canadian Journal of Statistics, 0, , .	0.9	0
353	Multistate Models for the Analysis of Life History Data. , 0, , .		50
354	Doubly weighted estimating equations and weighted multiple imputation for causal inference with an incomplete subgroup variable. Biostatistics and Epidemiology, 0, , 1-19.	0.4	0
355	The polytomous discrimination index for predictionÂinvolving multistate processes underÂintermittent observation. Statistics in Medicine, 0, , .	1.6	1
356	Adaptive responseâ€dependent twoâ€phase designs: Some results on robustness and efficiency. Statistics in Medicine, 0, , .	1.6	10